CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its participation in two November conferences, the Challenges and Opportunities for Mesenchymal Stem Cells digital conference being held November 17-18, 2022 and A.G.P.’s Biotech Conference on November 30, 2022. Robert W. Mays, M.D., Ph.D., Executive Vice President … [Read more…]

– IPX203 could offer people living with Parkinson’s disease a longer duration of symptom control with less frequent dosing compared to IR CD/LD treatment – The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of June 30, 2023. BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug … [Read more…]

NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: Jefferies London Healthcare Conference in London, United Kingdom on Tuesday, November 15, 2022, at 8:35 a.m. GMT … [Read more…]

Clinical activity observed in third dosing cohort and sustained clinical benefit in second cohort AUSTIN, Texas & SOUTH SAN FRANCISCO, Calif. & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced updated … [Read more…]

Tremeau is presenting two abstracts, highlighting the following: TRM-201 achieves comparable exposures of rofecoxib at a lower nominal dose (17.5 mg) compared to historical VIOXX 25 mg Rofecoxib’s favorable gastrointestinal tolerability profile enabled chronic off-label use of VIOXX’s acute dose (50 mg), leading to a perception of a unique CV safety risk CONCORD, Mass.–(BUSINESS WIRE)–Tremeau … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that its abstract highlighting data from the ongoing Phase 2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), was accepted for poster presentation at … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “CRISPR and CAS Genes Market Analysis by Product & Service, by Application by End user, and by Region – Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The CRISPR and CAS genes market size is estimated to be USD 1095 million in 2021 and is expected to witness a CAGR … [Read more…]

CareDx Leads Scientific Evidence with Over 100 Peer-Reviewed Publications Supporting the Clinical Use of AlloSure and AlloMap for Organ Transplant Patients BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the five-year anniversary … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Proteomic Biomarker Analytics Markets. Forecasts by Application, Technology, Product and Place. With Executive and Consultant Guides, Including Customized Forecasting and Analysis. 2022 to 2026” report has been added to ResearchAndMarkets.com’s offering. Proteomics is going mainstream. Where genomics couldn’t find all the answers proteomics is stepping up to the plate. Who will be the … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Endoscopy Visualization Systems Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update” report has been added to ResearchAndMarkets.com’s offering. Scope of the report Extensive coverage of the Endoscopy Visualization Systems under development The report reviews details of major pipeline products which includes, product description, licensing … [Read more…]